Eric Yee
Concepts (243)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Ampulla of Vater | 4 | 2018 | 17 | 1.060 |
Why?
| Intestinal Mucosa | 3 | 2020 | 274 | 0.790 |
Why?
| Colitis | 4 | 2020 | 52 | 0.650 |
Why?
| Gastritis | 1 | 2018 | 36 | 0.640 |
Why?
| Crohn Disease | 4 | 2021 | 96 | 0.640 |
Why?
| Adenoma, Liver Cell | 1 | 2016 | 9 | 0.570 |
Why?
| Placenta Diseases | 1 | 2016 | 12 | 0.570 |
Why?
| Pregnancy Complications, Neoplastic | 1 | 2016 | 21 | 0.560 |
Why?
| Adenosine Deaminase | 3 | 2021 | 4 | 0.410 |
Why?
| Liver Cirrhosis | 3 | 2018 | 216 | 0.400 |
Why?
| Gastrointestinal Agents | 2 | 2021 | 37 | 0.390 |
Why?
| Brenner Tumor | 1 | 2010 | 1 | 0.380 |
Why?
| Magnetic Resonance Imaging | 6 | 2020 | 1603 | 0.370 |
Why?
| Immunity, Innate | 3 | 2020 | 113 | 0.360 |
Why?
| Pancreatic Neoplasms | 3 | 2018 | 235 | 0.360 |
Why?
| Intercellular Signaling Peptides and Proteins | 2 | 2021 | 123 | 0.350 |
Why?
| Cannabidiol | 2 | 2020 | 35 | 0.350 |
Why?
| Antibodies, Monoclonal, Humanized | 2 | 2021 | 239 | 0.340 |
Why?
| Liver | 6 | 2022 | 1246 | 0.320 |
Why?
| Adenosine Triphosphatases | 2 | 2017 | 88 | 0.310 |
Why?
| Carcinoma, Renal Cell | 2 | 2020 | 119 | 0.280 |
Why?
| Common Bile Duct Diseases | 2 | 2015 | 8 | 0.280 |
Why?
| Colitis, Ulcerative | 2 | 2016 | 52 | 0.270 |
Why?
| Ovarian Neoplasms | 1 | 2010 | 471 | 0.270 |
Why?
| Kidney Neoplasms | 2 | 2020 | 195 | 0.260 |
Why?
| Humans | 32 | 2021 | 54132 | 0.260 |
Why?
| Membrane Proteins | 2 | 2018 | 391 | 0.250 |
Why?
| Immunohistochemistry | 4 | 2018 | 1097 | 0.250 |
Why?
| Alanine Transaminase | 2 | 2023 | 151 | 0.230 |
Why?
| Colonoscopy | 3 | 2020 | 105 | 0.220 |
Why?
| Liver Diseases | 1 | 2023 | 87 | 0.220 |
Why?
| Acetaminophen | 3 | 2023 | 349 | 0.220 |
Why?
| Autocrine Communication | 1 | 2021 | 10 | 0.210 |
Why?
| Kupffer Cells | 1 | 2021 | 18 | 0.210 |
Why?
| Paracrine Communication | 1 | 2021 | 12 | 0.210 |
Why?
| Biopsy | 3 | 2020 | 694 | 0.210 |
Why?
| Female | 19 | 2021 | 28437 | 0.210 |
Why?
| Mice | 10 | 2023 | 6436 | 0.200 |
Why?
| Biological Factors | 1 | 2021 | 13 | 0.200 |
Why?
| Common Bile Duct Neoplasms | 3 | 2015 | 11 | 0.200 |
Why?
| Predictive Value of Tests | 3 | 2020 | 1053 | 0.200 |
Why?
| Monocytes | 1 | 2021 | 156 | 0.190 |
Why?
| Endoscopy, Gastrointestinal | 2 | 2018 | 75 | 0.190 |
Why?
| Toll-Like Receptor 9 | 1 | 2020 | 11 | 0.190 |
Why?
| Plant Extracts | 2 | 2020 | 193 | 0.190 |
Why?
| Enterotoxins | 1 | 2020 | 12 | 0.190 |
Why?
| Colon | 2 | 2020 | 109 | 0.190 |
Why?
| Adult | 13 | 2021 | 14196 | 0.190 |
Why?
| Liver Neoplasms | 2 | 2015 | 353 | 0.190 |
Why?
| Cannabis | 2 | 2020 | 145 | 0.190 |
Why?
| Bacterial Toxins | 1 | 2020 | 61 | 0.190 |
Why?
| Abdomen | 1 | 2020 | 83 | 0.190 |
Why?
| Apyrase | 2 | 2017 | 16 | 0.180 |
Why?
| Clostridium Infections | 1 | 2020 | 62 | 0.180 |
Why?
| Male | 19 | 2022 | 27350 | 0.180 |
Why?
| Hepatic Veno-Occlusive Disease | 1 | 2019 | 10 | 0.180 |
Why?
| Methionine | 1 | 2020 | 147 | 0.180 |
Why?
| Cell Proliferation | 3 | 2018 | 1099 | 0.180 |
Why?
| Methamphetamine | 1 | 2022 | 233 | 0.170 |
Why?
| Colonic Pouches | 2 | 2015 | 6 | 0.170 |
Why?
| Gastrointestinal Tract | 1 | 2020 | 135 | 0.170 |
Why?
| Claudin-1 | 1 | 2018 | 5 | 0.170 |
Why?
| Zonula Occludens-1 Protein | 1 | 2018 | 7 | 0.170 |
Why?
| Lipase | 1 | 2018 | 18 | 0.160 |
Why?
| Animals | 11 | 2023 | 14435 | 0.160 |
Why?
| Observer Variation | 1 | 2018 | 139 | 0.160 |
Why?
| Cation Transport Proteins | 1 | 2018 | 28 | 0.160 |
Why?
| Enteric Nervous System | 1 | 2017 | 2 | 0.160 |
Why?
| Cholangiocarcinoma | 1 | 2017 | 30 | 0.160 |
Why?
| Bile Duct Neoplasms | 1 | 2017 | 33 | 0.160 |
Why?
| Transcriptome | 2 | 2020 | 347 | 0.160 |
Why?
| Serum | 1 | 2017 | 40 | 0.160 |
Why?
| Liver Regeneration | 1 | 2017 | 57 | 0.150 |
Why?
| Lanthanum | 1 | 2017 | 3 | 0.150 |
Why?
| Upper Gastrointestinal Tract | 1 | 2017 | 4 | 0.150 |
Why?
| Hyperphosphatemia | 1 | 2017 | 2 | 0.150 |
Why?
| Transaminases | 1 | 2017 | 14 | 0.150 |
Why?
| Middle Aged | 12 | 2021 | 13094 | 0.150 |
Why?
| Pneumatosis Cystoides Intestinalis | 1 | 2017 | 7 | 0.150 |
Why?
| Anorexia Nervosa | 1 | 2017 | 7 | 0.150 |
Why?
| Decision Support Techniques | 1 | 2017 | 73 | 0.150 |
Why?
| Diffusion Magnetic Resonance Imaging | 1 | 2017 | 127 | 0.150 |
Why?
| Paneth Cells | 1 | 2016 | 1 | 0.150 |
Why?
| Immunity, Mucosal | 1 | 2016 | 19 | 0.150 |
Why?
| Dietary Supplements | 1 | 2020 | 450 | 0.150 |
Why?
| Cholangitis, Sclerosing | 1 | 2016 | 8 | 0.140 |
Why?
| Insulinoma | 1 | 2016 | 7 | 0.140 |
Why?
| Pregnancy, Twin | 1 | 2016 | 7 | 0.140 |
Why?
| Th1 Cells | 1 | 2016 | 50 | 0.140 |
Why?
| Adaptive Immunity | 1 | 2016 | 39 | 0.140 |
Why?
| Gene Expression Regulation, Neoplastic | 2 | 2018 | 867 | 0.140 |
Why?
| Enteral Nutrition | 1 | 2017 | 136 | 0.140 |
Why?
| Retrospective Studies | 5 | 2021 | 6387 | 0.140 |
Why?
| Th17 Cells | 1 | 2016 | 26 | 0.140 |
Why?
| Hepatitis, Autoimmune | 1 | 2016 | 29 | 0.140 |
Why?
| Incidental Findings | 1 | 2016 | 42 | 0.140 |
Why?
| Diagnosis, Differential | 5 | 2020 | 1133 | 0.140 |
Why?
| Adenomatous Polyposis Coli | 1 | 2015 | 8 | 0.140 |
Why?
| Carcinoma, Pancreatic Ductal | 1 | 2016 | 35 | 0.140 |
Why?
| Serine Endopeptidases | 1 | 2016 | 57 | 0.140 |
Why?
| Multidetector Computed Tomography | 1 | 2015 | 9 | 0.140 |
Why?
| Hypoglycemia | 1 | 2016 | 61 | 0.130 |
Why?
| Bariatric Surgery | 1 | 2016 | 43 | 0.130 |
Why?
| Angiomyolipoma | 1 | 2015 | 10 | 0.130 |
Why?
| Fatty Acids | 1 | 2016 | 177 | 0.130 |
Why?
| Proto-Oncogene Proteins | 1 | 2016 | 163 | 0.130 |
Why?
| Rectal Neoplasms | 1 | 2015 | 52 | 0.130 |
Why?
| Kwashiorkor | 1 | 2014 | 2 | 0.130 |
Why?
| Inflammatory Bowel Diseases | 1 | 2015 | 57 | 0.130 |
Why?
| Tomography, X-Ray Computed | 3 | 2015 | 1210 | 0.130 |
Why?
| Paraganglioma | 1 | 2014 | 12 | 0.130 |
Why?
| Antigens, CD | 1 | 2016 | 242 | 0.130 |
Why?
| Gastric Bypass | 1 | 2014 | 22 | 0.130 |
Why?
| Macrophages | 1 | 2017 | 401 | 0.130 |
Why?
| Neoplasms, Muscle Tissue | 1 | 2014 | 13 | 0.130 |
Why?
| Reproducibility of Results | 1 | 2018 | 1307 | 0.120 |
Why?
| Gastrointestinal Hemorrhage | 1 | 2014 | 80 | 0.120 |
Why?
| Dacryocystitis | 1 | 2013 | 5 | 0.120 |
Why?
| Nasolacrimal Duct | 1 | 2013 | 10 | 0.120 |
Why?
| Disease Models, Animal | 4 | 2020 | 1645 | 0.120 |
Why?
| Aged | 8 | 2021 | 10059 | 0.120 |
Why?
| Mice, Inbred C57BL | 4 | 2020 | 2021 | 0.110 |
Why?
| Anesthetics, Local | 1 | 2013 | 74 | 0.110 |
Why?
| Colorectal Neoplasms | 1 | 2015 | 237 | 0.110 |
Why?
| Cocaine | 1 | 2013 | 184 | 0.110 |
Why?
| Adenocarcinoma | 1 | 2016 | 428 | 0.100 |
Why?
| Mice, Knockout | 3 | 2020 | 941 | 0.100 |
Why?
| Sensitivity and Specificity | 3 | 2020 | 925 | 0.100 |
Why?
| Sulfonamides | 1 | 2012 | 147 | 0.100 |
Why?
| Pyrimidines | 1 | 2012 | 196 | 0.100 |
Why?
| Protein Kinase Inhibitors | 1 | 2012 | 216 | 0.100 |
Why?
| V-Set Domain-Containing T-Cell Activation Inhibitor 1 | 1 | 2010 | 4 | 0.090 |
Why?
| Cocaine-Related Disorders | 1 | 2013 | 246 | 0.090 |
Why?
| Rats, Wistar | 2 | 2022 | 243 | 0.090 |
Why?
| CA-125 Antigen | 1 | 2010 | 20 | 0.090 |
Why?
| Carcinoembryonic Antigen | 1 | 2010 | 15 | 0.090 |
Why?
| Pregnancy | 1 | 2016 | 2614 | 0.080 |
Why?
| Postoperative Complications | 1 | 2015 | 1036 | 0.080 |
Why?
| Prospective Studies | 3 | 2021 | 2607 | 0.080 |
Why?
| Dextran Sulfate | 2 | 2017 | 10 | 0.080 |
Why?
| Liver Function Tests | 2 | 2017 | 43 | 0.070 |
Why?
| Dose-Response Relationship, Drug | 2 | 2020 | 1478 | 0.070 |
Why?
| Young Adult | 3 | 2020 | 4320 | 0.060 |
Why?
| Rats | 2 | 2022 | 3435 | 0.060 |
Why?
| Disease Progression | 2 | 2018 | 915 | 0.060 |
Why?
| Alanine | 1 | 2023 | 44 | 0.060 |
Why?
| Pyruvic Acid | 1 | 2023 | 24 | 0.060 |
Why?
| Case-Control Studies | 2 | 2017 | 1242 | 0.060 |
Why?
| Glutathione | 1 | 2023 | 330 | 0.050 |
Why?
| Oxidation-Reduction | 1 | 2023 | 384 | 0.050 |
Why?
| Adolescent | 3 | 2020 | 6890 | 0.050 |
Why?
| Amphetamine | 1 | 2022 | 42 | 0.050 |
Why?
| Proto-Oncogene Proteins c-sis | 1 | 2021 | 9 | 0.050 |
Why?
| Half-Life | 1 | 2022 | 95 | 0.050 |
Why?
| Signal Transduction | 2 | 2020 | 1754 | 0.050 |
Why?
| Aged, 80 and over | 2 | 2020 | 3442 | 0.050 |
Why?
| Anti-Bacterial Agents | 2 | 2020 | 816 | 0.050 |
Why?
| Antioxidants | 1 | 2023 | 297 | 0.050 |
Why?
| Mucin-2 | 1 | 2020 | 9 | 0.050 |
Why?
| Drug Monitoring | 1 | 2020 | 85 | 0.050 |
Why?
| Molecular Chaperones | 1 | 2020 | 65 | 0.050 |
Why?
| Adenosylhomocysteinase | 1 | 2020 | 11 | 0.050 |
Why?
| Alcohol Dehydrogenase | 1 | 2020 | 31 | 0.050 |
Why?
| Aldehyde Dehydrogenase | 1 | 2020 | 27 | 0.050 |
Why?
| Ileum | 1 | 2020 | 108 | 0.050 |
Why?
| DNA, Bacterial | 1 | 2020 | 172 | 0.050 |
Why?
| Chemokines | 1 | 2020 | 96 | 0.050 |
Why?
| Treatment Outcome | 2 | 2021 | 5596 | 0.040 |
Why?
| Epithelial Cells | 1 | 2021 | 256 | 0.040 |
Why?
| Mice, Inbred Strains | 1 | 2019 | 198 | 0.040 |
Why?
| Drug Synergism | 1 | 2019 | 171 | 0.040 |
Why?
| Lipoproteins, VLDL | 1 | 2018 | 16 | 0.040 |
Why?
| Lipoproteins, HDL | 1 | 2018 | 21 | 0.040 |
Why?
| Drug Overdose | 1 | 2020 | 154 | 0.040 |
Why?
| Body Weight | 1 | 2020 | 583 | 0.040 |
Why?
| Evaluation Studies as Topic | 1 | 2017 | 108 | 0.040 |
Why?
| Epithelial-Mesenchymal Transition | 1 | 2018 | 53 | 0.040 |
Why?
| Oxidative Stress | 1 | 2023 | 953 | 0.040 |
Why?
| Neoplasm Grading | 1 | 2017 | 131 | 0.040 |
Why?
| Refeeding Syndrome | 1 | 2017 | 1 | 0.040 |
Why?
| Bile Ducts | 1 | 2017 | 54 | 0.040 |
Why?
| Dexamethasone | 1 | 2020 | 448 | 0.040 |
Why?
| Magnetic Resonance Spectroscopy | 1 | 2018 | 252 | 0.040 |
Why?
| Hepatitis | 1 | 2017 | 22 | 0.040 |
Why?
| ROC Curve | 1 | 2017 | 260 | 0.040 |
Why?
| Cell Movement | 1 | 2018 | 276 | 0.040 |
Why?
| Risk Factors | 2 | 2016 | 3936 | 0.040 |
Why?
| Severity of Illness Index | 1 | 2020 | 1084 | 0.040 |
Why?
| RNA, Messenger | 1 | 2020 | 1222 | 0.040 |
Why?
| Cytokines | 1 | 2020 | 678 | 0.040 |
Why?
| Receptor, Adenosine A2A | 1 | 2016 | 3 | 0.040 |
Why?
| Algorithms | 1 | 2020 | 697 | 0.040 |
Why?
| Genotype | 1 | 2018 | 607 | 0.040 |
Why?
| Lipoproteins, LDL | 1 | 2018 | 195 | 0.040 |
Why?
| Phosphoric Diester Hydrolases | 1 | 2016 | 29 | 0.040 |
Why?
| Transcription, Genetic | 1 | 2018 | 419 | 0.040 |
Why?
| Receptors, G-Protein-Coupled | 1 | 2016 | 55 | 0.040 |
Why?
| Interleukin-17 | 1 | 2016 | 38 | 0.040 |
Why?
| Malnutrition | 1 | 2017 | 83 | 0.030 |
Why?
| Anastomosis, Surgical | 1 | 2015 | 73 | 0.030 |
Why?
| Carcinoma in Situ | 1 | 2016 | 74 | 0.030 |
Why?
| Postoperative Period | 1 | 2016 | 191 | 0.030 |
Why?
| Organometallic Compounds | 1 | 2015 | 46 | 0.030 |
Why?
| Colonic Polyps | 1 | 2015 | 44 | 0.030 |
Why?
| Neoplasm Staging | 1 | 2018 | 801 | 0.030 |
Why?
| Pancreatic Function Tests | 1 | 2014 | 1 | 0.030 |
Why?
| Endoscopy | 1 | 2016 | 131 | 0.030 |
Why?
| Malabsorption Syndromes | 1 | 2014 | 9 | 0.030 |
Why?
| Image Enhancement | 1 | 2015 | 55 | 0.030 |
Why?
| Obesity, Morbid | 1 | 2016 | 90 | 0.030 |
Why?
| Polymorphism, Single Nucleotide | 1 | 2018 | 558 | 0.030 |
Why?
| Kidney Failure, Chronic | 1 | 2017 | 229 | 0.030 |
Why?
| Population Surveillance | 1 | 2015 | 183 | 0.030 |
Why?
| Early Detection of Cancer | 1 | 2016 | 159 | 0.030 |
Why?
| Genetic Predisposition to Disease | 1 | 2018 | 575 | 0.030 |
Why?
| Mammary Glands, Human | 1 | 2014 | 15 | 0.030 |
Why?
| Blotting, Western | 1 | 2016 | 685 | 0.030 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2016 | 682 | 0.030 |
Why?
| Ultrasonography, Doppler, Color | 1 | 2014 | 34 | 0.030 |
Why?
| Models, Biological | 1 | 2018 | 824 | 0.030 |
Why?
| Recurrence | 1 | 2016 | 692 | 0.030 |
Why?
| Contrast Media | 1 | 2015 | 221 | 0.030 |
Why?
| Lacrimal Duct Obstruction | 1 | 2013 | 6 | 0.030 |
Why?
| Body Mass Index | 1 | 2017 | 710 | 0.030 |
Why?
| Dacryocystorhinostomy | 1 | 2013 | 9 | 0.030 |
Why?
| Administration, Intranasal | 1 | 2013 | 29 | 0.030 |
Why?
| Azithromycin | 1 | 2013 | 42 | 0.030 |
Why?
| Cell Line, Tumor | 1 | 2018 | 1542 | 0.030 |
Why?
| Fluoroquinolones | 1 | 2013 | 37 | 0.030 |
Why?
| Gene Expression | 1 | 2016 | 667 | 0.030 |
Why?
| Flow Cytometry | 1 | 2016 | 548 | 0.030 |
Why?
| Mass Screening | 1 | 2015 | 369 | 0.030 |
Why?
| Cross-Sectional Studies | 1 | 2017 | 1678 | 0.030 |
Why?
| Indazoles | 1 | 2012 | 55 | 0.030 |
Why?
| Fatal Outcome | 1 | 2012 | 225 | 0.030 |
Why?
| Vascular Endothelial Growth Factor A | 1 | 2012 | 231 | 0.030 |
Why?
| Combined Modality Therapy | 1 | 2013 | 694 | 0.020 |
Why?
| Prognosis | 1 | 2016 | 2116 | 0.020 |
Why?
| Follow-Up Studies | 1 | 2016 | 2384 | 0.020 |
Why?
| Time Factors | 1 | 2016 | 3223 | 0.020 |
Why?
| Infant | 1 | 2016 | 3797 | 0.020 |
Why?
| Child, Preschool | 1 | 2016 | 4132 | 0.020 |
Why?
| Child | 1 | 2016 | 7312 | 0.010 |
Why?
|
|
Yee's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|